TY - JOUR
T1 - Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe
AU - Boccardi, Marina
AU - Monsch, Andreas U
AU - Ferrari, Clarissa
AU - Altomare, Daniele
AU - Berres, Manfred
AU - Bos, Isabelle
AU - Buchmann, Andreas
AU - Cerami, Chiara
AU - Didic, Mira
AU - Festari, Cristina
AU - Nicolosi, Valentina
AU - Sacco, Leonardo
AU - Aerts, Liesbeth
AU - Albanese, Emiliano
AU - Annoni, Jean-Marie
AU - Ballhausen, Nicola
AU - Chicherio, Christian
AU - Démonet, Jean-François
AU - Descloux, Virginie
AU - Diener, Suzie
AU - Ferreira, Daniel
AU - Georges, Jean
AU - Gietl, Anton
AU - Girtler, Nicola
AU - Kilimann, Ingo
AU - Klöppel, Stefan
AU - Kustyniuk, Nicole
AU - Mecocci, Patrizia
AU - Mella, Nathalie
AU - Pigliautile, Martina
AU - Seeher, Katrin
AU - Shirk, Steven D
AU - Toraldo, Alessio
AU - Brioschi-Guevara, Andrea
AU - Chan, Kwun C G
AU - Crane, Paul K
AU - Dodich, Alessandra
AU - Grazia, Alice
AU - Kochan, Nicole A
AU - de Oliveira, Fabricio Ferreira
AU - Nobili, Flavio
AU - Kukull, Walter
AU - Peters, Oliver
AU - Ramakers, Inez
AU - Sachdev, Perminder S
AU - Teipel, Stefan
AU - Visser, Pieter Jelle
AU - Wagner, Michael
AU - Weintraub, Sandra
AU - Westman, Eric
AU - Consortium for the Harmonization of Neuropsychological Assessment for Neurocognitive Disorders (https://nextcloud.dzne.de/index.php/s/EwXjLab9caQTbQe)
N1 - Funding information:
The Geneva Workshop was funded by the Swiss National Science Foundation (grant number ISZEZO_180198), Alzheimer Forum Switzerland and MindMaze. M. Boccardi was supported in part by the EU-EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (grant no. 115952; recipient: Giovanni Frisoni, AMYPAD project). I. Bos and P.J. Visser were supported by the Innovative Medicine Initiative Joint Undertaking. P.J.V. participation was also supported by ZONmW. The participation of W. Kukull was supported by NIH (U01 AG016976); participation of P. Sachdev was supported by NHMRC Australia. C. Ferrari was supported by the Italian Ministry of Health (Ricerca Corrente).
PY - 2022
Y1 - 2022
N2 - Introduction: Harmonized neuropsychological assessment for neurocognitive disorders, an international priority for valid and reliable diagnostic procedures, has been achieved only in specific countries or research contexts.Methods: To harmonize the assessment of mild cognitive impairment in Europe, a workshop (Geneva, May 2018) convened stakeholders, methodologists, academic, and non-academic clinicians and experts from European, US, and Australian harmonization initiatives.Results: With formal presentations and thematic working-groups we defined a standard battery consistent with the U.S. Uniform DataSet, version 3, and homogeneous methodology to obtain consistent normative data across tests and languages. Adaptations consist of including two tests specific to typical Alzheimer's disease and behavioral variant frontotemporal dementia. The methodology for harmonized normative data includes consensus definition of cognitively normal controls, classification of confounding factors (age, sex, and education), and calculation of minimum sample sizes.Discussion: This expert consensus allows harmonizing the diagnosis of neurocognitive disorders across European countries and possibly beyond.
AB - Introduction: Harmonized neuropsychological assessment for neurocognitive disorders, an international priority for valid and reliable diagnostic procedures, has been achieved only in specific countries or research contexts.Methods: To harmonize the assessment of mild cognitive impairment in Europe, a workshop (Geneva, May 2018) convened stakeholders, methodologists, academic, and non-academic clinicians and experts from European, US, and Australian harmonization initiatives.Results: With formal presentations and thematic working-groups we defined a standard battery consistent with the U.S. Uniform DataSet, version 3, and homogeneous methodology to obtain consistent normative data across tests and languages. Adaptations consist of including two tests specific to typical Alzheimer's disease and behavioral variant frontotemporal dementia. The methodology for harmonized normative data includes consensus definition of cognitively normal controls, classification of confounding factors (age, sex, and education), and calculation of minimum sample sizes.Discussion: This expert consensus allows harmonizing the diagnosis of neurocognitive disorders across European countries and possibly beyond.
KW - ALZHEIMERS-DISEASE
KW - AMNESTIC SYNDROME
KW - Alzheimer&apos
KW - BEHAVIORAL VARIANT
KW - COGNITIVE IMPAIRMENT
KW - CONSENSUS STATEMENT
KW - DATA SET UDS
KW - DIFFERENTIAL-DIAGNOSIS
KW - MONTE-CARLO
KW - SAMPLE-SIZE
KW - SELECTIVE REMINDING TEST
KW - cognitive assessment
KW - diagnosis
KW - mild cognitive impairment
KW - mild neurocognitive disorders
KW - s disease
KW - standard neuropsychological assessment
UR - http://www.scopus.com/inward/record.url?scp=85105700631&partnerID=8YFLogxK
U2 - 10.1002/alz.12365
DO - 10.1002/alz.12365
M3 - Article
C2 - 33984176
SN - 1552-5260
VL - 18
SP - 29
EP - 42
JO - Alzheimers & Dementia
JF - Alzheimers & Dementia
IS - 1
ER -